GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avisa Diagnostics Inc (GREY:FOGCF) » Definitions » Volatility

Avisa Diagnostics (Avisa Diagnostics) Volatility : N/A% (As of Jun. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Avisa Diagnostics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

Avisa Diagnostics does not have enough data to calculate Volatility.


Competitive Comparison of Avisa Diagnostics's Volatility

For the Medical Devices subindustry, Avisa Diagnostics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avisa Diagnostics's Volatility Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avisa Diagnostics's Volatility distribution charts can be found below:

* The bar in red indicates where Avisa Diagnostics's Volatility falls into.



Avisa Diagnostics  (GREY:FOGCF) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avisa Diagnostics  (GREY:FOGCF) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Avisa Diagnostics Volatility Related Terms

Thank you for viewing the detailed overview of Avisa Diagnostics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Avisa Diagnostics (Avisa Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
1660A Old Pecos Trail, Santa Fe, NM, USA, 87505
Avisa Diagnostics Inc is a clinical-stage medical device company developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials.